Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

PURPOSE: To determine whether (1) immunohistochemical (IHC) HER2 status (ie, 2+ or 3+), (2) degree of fluorescence in situ hybridization (FISH) amplification according to (2a) HER2/CEP17 ratio or (2b) HER2 gene copy number, or (3) polysomy significantly influenced clinical outcome for patients with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Dowsett, Mitch, Procter, Marion, McCaskill-Stevens, Worta, de Azambuja, Evandro, Dafni, Urania, Rueschoff, Josef, Jordan, Bruce, Dolci, Stella, Abramovitz, Mark, Stoss, Oliver, Viale, Giuseppe, Gelber, Richard D., Piccart-Gebhart, Martine, Leyland-Jones, Brian
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2009
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2701645/
https://ncbi.nlm.nih.gov/pubmed/19364966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.7939
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia